HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Molecular diagnosis (Print)

• Publication date

  2000-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF03262077PMID 11070154
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HER-2/neu Gene and protein in breast cancer

  2004cited by this paper
• Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.

  2000cited by this paper
• HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement.

  2000cited by this paper
• Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.

  1999cited by this paper
• Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.

  1999cited by this paper
• Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.

  1999cited by this paper
• HER-2/neu testing comes of age.

  1999cited by this paper
• HER-2/neu (c-erb-B2) gene and protein in breast cancer.

  1999cited by this paper
• Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

  1999cited by this paper
• Increased HER2 with U.S. Food and Drug Administration-approved antibody.

  1999cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

  1998cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer.

  1998cited by this paper
• Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

  1998cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

  1996cited by this paper
• Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

  1996cited by this paper
• c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer.

  1995cited by this paper
• C-erbB-2 immunostaining: problems with interpretation.

  1994cited by this paper
• Prognostic value of c‐erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol

  1994cited by this paper
• ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.

  1994cited by this paper
• Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

  1994cited by this paper
• Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

  1994cited by this paper
• Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

  1993cited by this paper
• C‐erbb‐2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node‐positive breast cancer

  1992cited by this paper
• HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.

  1992cited by this paper
• Adjuvant therapy for node-negative breast cancer.

  1989cited by this paper
• Adjuvant therapy in node-negative breast cancer

  1989cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper

• HER3 receptor and its role in the therapeutic management of metastatic breast cancer

  2024cites this paper
• Multiparametric profiling of HER2-enriched extracellular vesicles in breast cancer using Single Extracellular VEsicle Nanoscopy

  2024cites this paper
• Companion Diagnostics (CDx) Based on Molecular Biology Techniques

  2024cites this paper
• Evaluation of HER2Neu Status in Periampullary Cancers in Tertiary Care Centre in Northern India: A Three-Year Retrospective Study

  2023cites this paper
• Molecular Imaging of HER2 in Patient Tissues with Touch Prep-Quantitative Single Molecule Localization Microscopy.

  2022cites this paper
• Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer

  2022cites this paper
• The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review

  2022cites this paper
• Breast Carcinoma – A Comparative Study of Immunohistochemistry and Fluorescence in Situ Hybridization for Her-2 Assessment and Association of ER, PR, HER-2 and Ki-67 Expression with Clinico-Pathological Parameters

  2022cites this paper
• HER2 Testing in Invasive Breast Cancer: A Comparison Between Immunohistochemistry and Fluorescence In Situ Hybridization Assays

  2020cites this paper
• HER2/neu status detection in breast carcinoma: Is FISH the preferred approach over IHC

  2019cites this paper
• The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution

  2019cites this paper
• The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach

  2019cites this paper
• Cytogenetic methods and findings in human solid tumors

  2017cites this paper
• Determination of HER2 Gene Amplification using Chromogenic in Situ Hybridization (CISH) in Iraqi Patients with Breast Carcinoma

  2017cites this paper
• Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications

  2017cites this paper
• Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms

  2017cites this paper
• Revieiv Evaluation of HER 2 Status imHuman Breast Carcinoma

  2017cites this paper
• Determination of HER 2 Gene Amplification using Chromogenic in Situ Hybridization ( CISH ) in Iraqi Patients with Breast Carcinoma

  2017cites this paper
• 1 Molecular Biology of Endometrial Carcinoma

  2017cites this paper
• Tumor infiltrating immune cells in gliomas and meningiomas.

  2016cites this paper
• Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer:  A Cohort Study Emphasizing Equivocal Cases.

  2016cites this paper
• Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables

  2016cites this paper
• Interobserver reproducibility for HER2/neu immunohistochemistry: A comparison of reproducibility for the HercepTest™ and the 4B5 antibody clone.

  2016cites this paper
• Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.

  2015cites this paper
• Pharmaceutical policy in Australia : developing methods to manage uncertainty in health technology assessment

  2015cites this paper
• Evaluation of HER2 Protein Expression Using 2 New Monoclonal Antibodies

  2015cites this paper
• A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer

  2015cites this paper
• A Comparison of IHC and FISH Cytogenetic Methods in the Evaluation of HER2 Status in Breast Cancer.

  2015cites this paper
• Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.

  2015cites this paper
• Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.

  2014cites this paper
• Theranostic and molecular classification of breast cancer.

  2014cites this paper
• Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.

  2013cites this paper
• Detection of HER-2/neu Amplification on Fine Needle Aspirates of Breast Cancer Using Fluorescence in Situ Hybridization

  2013cites this paper
• HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies

  2013cites this paper
• Avaliação de HER-2 em câncer de pâncreas : diferenças entre as classificações HercepTest™ e ToGA Trial e correlação com a sobrevida

  2012cites this paper
• Molecular Biology of Endometrial Carcinoma

  2012cites this paper
• Adjusting for partial verification or workup bias in meta-analyses of diagnostic accuracy studies.

  2012cites this paper
• Molecular biology of endometrial carcinoma prognostic factors

  2012cites this paper
• Avaliação de HER-2 em Câncer de Pâncreas: Diferenças entre as Classificações HercepTest™ e ToGA Trial e Correlação com a Sobrevida

  2012cites this paper
• Title : Triple-negative breast cancer is associated with EGFR , CK 5 / 6 and c-KIT expression in Malaysian women

  2012influential citation
• Looking for factors predicting outcome of breast carcinoma using tissue microarrays

  2012cites this paper
• Profiling post translational modification of histone and p53 in human breast carcinomas

  2011cites this paper
• Prognostication and Prediction in Anatomic Pathology: Carcinoma of the Breast as an Illustrative Model

  2011cites this paper
• Specimen Processing in Pathology

  2011cites this paper
• Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy

  2011cites this paper
• Her-2/neu Overexpression Due to Polysomy 17 in Breast Cancer: Molecular Testing to Guide Therapeutic Options

  2011cites this paper
• Testing for HER2 in Breast Cancer: A Continuing Evolution

  2010cites this paper
• Impact of Clinical and Non-Clinical Factors on the Choice of HER2 Test for Breast Cancer

  2010cites this paper
• An Alternative and Reliable Real-time Quantitative PCR Method to Determine HER2/neu Amplification in Breast Cancer

  2009cites this paper
• The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

  2009cites this paper
• Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer

  2009cites this paper
• Lower HER‐2/chromosome enumeration probe 17 ratio in cytologic HER‐2 fluorescence in situ hybridization for breast cancers

  2008cites this paper
• High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

  2008cites this paper
• Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study.

  2008cites this paper
• Current issues in ER and HER2 testing by IHC in breast cancer

  2008cites this paper
• Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?

  2007cites this paper
• Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

  2007cites this paper
• Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.

  2007cites this paper
• Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.

  2007cites this paper
• Immunocytochemistry and Fluorescence in Situ Hybridization in HER-2/neu Status in Cell Block Preparations

  2007cites this paper
• Immunohistochemical her-2/ Neu expression with gene amplification by fluorescence in situ hybridization for assessment in breast carcinomas.

  2007cites this paper
• HER2 testing: a review of detection methodologies and their clinical performance

  2007cites this paper
• Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the Breast: A Single Institution Experience

  2007cites this paper
• HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.

  2006cites this paper
• Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer

  2006cites this paper
• Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype

  2006cites this paper
• Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR — A comparison with immunohistochemical and FISH results

  2006cites this paper
• HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists.

  2006cites this paper
• Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France

  2006cites this paper
• In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.

  2006cites this paper
• Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIα-status of the primary tumor?

  2005cites this paper
• Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

  2005cites this paper
• Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.

  2005cites this paper
• Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

  2005cites this paper
• Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA)

  2005cites this paper
• Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma.

  2004cites this paper
• Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

  2004cites this paper
• Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome

  2004cites this paper
• HER-2 testing in breast cancer using parallel tissue-based methods.

  2004cites this paper
• Comparative Analysis Between the HER2 Status in Primary Breast Cancer Tissue and the Detection of Isolated Tumor Cells in the Bone Marrow

  2004cites this paper
• STK15/Aurora‐A expression in primary breast tumors is correlated with nuclear grade but not with prognosis

  2004cites this paper
• HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.

  2004cites this paper
• HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies.

  2004cites this paper
• HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

  2004cites this paper
• HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.

  2004cites this paper
• Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?

  2004cites this paper
• Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy.

  2003cites this paper
• The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

  2003cites this paper
• Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

  2002cites this paper
• Quantitation of erbB2 positivity for evaluation of high-risk patients

  2002cites this paper
• Synthetic peptides identified from phage-displayed combinatorial libraries as immunodiagnostic assay surrogate quality-control targets.

  2002cites this paper
• [Immunohistochemistry and genotype analysis of tumors. First part: Which future for the immunochemical diagnosis of cancer?].

  2002cites this paper
• Is fluorescence in situ hybridization really superior to HercepTest?

  2002cites this paper
• HER-2/neu Status: Comparison of Quantitative Immunohistochemistry by Automated Cellular Imaging and Fluorescence In Situ Hybridization

  2002cites this paper
• Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing.

  2002cites this paper
• HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.

  2002cites this paper
• Interobserver Interpretative Reproducibility of GOLDFISH, A First Generation Gold-Facilitated Autometallographic Bright Field In Situ Hybridization Assay for HER-2/neu Amplification in Invasive Mammary Carcinoma

  2002cites this paper
• Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma

  2002cites this paper
• Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.

  2002cites this paper
• Her-2/neu and breast cancer.

  2001cites this paper